3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
5
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Prolymphocytic
3
Breast Neoplasms
3
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Extranodal NK-T-Cell
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Interventions
Temozolomide
41
Radiotherapy
15
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
10
Bevacizumab
10
Irinotecan
9
Radiation
8
Nivolumab
7
Carmustine
7
Specimen Handling
6
Radiosurgery
6
Carboplatin
6
ribociclib
5
O(6)-benzylguanine
5
Imiquimod
5
IL13-PE38
5
Flucytosine
5
Filgrastim
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Aminolevulinic Acid
5
vandetanib
4
sargramostim
4
Topotecan
4
Lomustine
4
Imatinib Mesylate
4
Etoposide
4
Craniotomy
4
vocimagene amiretrorepvec
3
temsirolimus
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioma
×
Pharmacogenomic Testing
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled